Zacks Investment Research downgraded shares of TARGACEPT INC (TRGT) from OUTPERFORM to UNDERPERFORM on March 12, 2013, with a target price of $4.10.
TARGACEPT INC is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics, a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenia, pain and depression, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on TARGACEPT INC (TRGT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment